By: IPP Bureau
Last updated : September 05, 2025 6:16 pm
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Quotient Sciences, a leading global drug development and manufacturing accelerator, and CPI, the UK’s cutting-edge technology innovation centre, have signed a Memorandum of Understanding (MoU) to establish a groundbreaking joint venture aimed at transforming the future of RNA-based therapies.
By combining Quotient Sciences’ renowned Translational Pharmaceutics platform with CPI’s expertise in small-scale RNA manufacturing and lipid nanoparticle (LNP) encapsulation, the partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products. This bold move responds to the surging demand for agile solutions that speed up the delivery of life-changing RNA therapeutics.
“This is a pivotal moment for RNA drug development,” said Thierry Van Nieuwenhove, CEO of Quotient Sciences. “Together with CPI, we are creating an accelerated supply chain that can deliver clinical batches from plasmid to clinical dose in as little as two months. This game-changing capability offers a streamlined pathway to early-phase clinical trials, giving drug developers the agility to adjust formulations and dosing in real time, dramatically improving the chances of clinical success.”
The joint venture will integrate every critical stage of RNA development – from mRNA synthesis and LNP formulation to clinical manufacturing and early-phase human testing – under a single collaborative framework. This end-to-end approach not only shortens development timelines but also strengthens the likelihood of achieving clinical milestones, particularly in areas where drug delivery is crucial to therapeutic efficacy.
Frank Millar, CEO of CPI, commented: “We are proud to partner with Quotient Sciences on an initiative that represents a significant leap forward for the RNA ecosystem. Our shared vision is to unlock scalable and sustainable development pathways for mRNA therapies that can meet global health challenges head-on.”
With Translational Pharmaceutics already applied in more than 500 global programs for small molecule and peptide drug candidates, this collaboration marks its expansion into the fast-growing field of mRNA therapeutics.
Details of the joint venture – including its official name, brand identity, and operational roadmap – will be announced in the coming months as the collaboration takes shape.